- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Revealing Industry Payments to Docs Could Spur Legislation on Conflicts: Experts
The public will learn for the first time this fall exactly how much their doctors are paid by the drug companies and devicemakers whose products they use. But don't expect it to be the end of the inquiry.
The public will learn for the first time this fall exactly how much their doctors are paid by the drug companies and devicemakers whose products they use. But don't expect it to be the end of the inquiry.
More than 80% of the 665,000 U.S. physicians receive payments of some kind from drug companies, according to recent research summarized by Harvard health policy professor Eric Campbell. "Financial relationships are incredibly frequent," Campbell told a roomful of reporters Friday at the Association of Health Care Journalists annual conference in Denver. "It is almost difficult to find physicians who don't have relationships."
Despite the ubiquity of the payments and their potential to cause doctors to steer patients toward heavily promoted products, this September will mark the first time that the public will have access to a searchable database showing who's paying whom. The disclosures are mandated under the Physician Payments Sunshine Act provision in the Patient Protection and Affordable Care Act.
Read the full story here: http://bit.ly/1gXMxn8
Source: Modern Healthcare
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
